BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 9, 2026
Home » Blogs » BioWorld MedTech Perspectives » No excuses, get an EHR!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Imaging

No excuses, get an EHR!

July 20, 2012
By Amanda Pedersen

An acquaintance of mine who, like me, has inflammatory bowel disease, received a call recently from her local hospital informing her they had lost her MRI images. They found them, but she is concerned they will have to retake them anyway because at this point her images are no longer current enough for the doctor to make an informed treatment decision.

This is a prime example of why all hospitals should use electronic health records (EHRs). At a time when health IT (HIT) companies are cropping up faster than Starbucks coffee shops, and the federal government is handing out incentive funds to those hospitals who use electronic records, there is truly no excuse for not having an EHR system in place.

Asking patients to retake an MRI simply because they can’t keep their records together is not only inconvenient for the patient but extremely inefficient for the hospital. Assuming this sort of thing happens regularly, these are dollars the hospital is flushing away that could be invested in an EHR system.

Sure, there are initial costs involved with installing a reliable EHR system, but many of these costs are reimbursable under the American Recovery and Reinvestment Act and most HIT companies are eager to guide clients through the meaningful use requirements. It makes the company look good and it recovers critical funds for the hospitals to put to other uses, like saving lives.

Just as one example, we recently reported in Medical Device Daily that a financially-strapped 319-bed county hospital in California went live on Medsphere Systems’ OpenVista open source EHR. That hospital is expected, according to Medsphere, to receive “substantially more” in federal reimbursement than the five-year costs to acquire the system. It makes sense not only from a patient care standpoint but from a financial perspective also.

Medsphere President/CEO Irv Lichtenwald called the move a compelling example of responsible decision-making, and I agree. “Especially in these troubled economic times, public hospitals can still improve care without making financial matters worse for local government,” Lichtenwald said.

And of course Medsphere is not alone in the HIT market, the firm has plenty of competitors, all more than happy to help private and public hospitals alike experience similar financial gains by implementing these invaluable electronic records systems.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 8, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing